23andMe and Nightingale Health Join Forces

In order to evaluate Nightingale Health’s blood-based metabolomics panel in a group of 23andMe users, 23andMe and the business recently established a partnership.

Close to 5,000 users of 23andMe+ Premium and Total Health will receive complimentary blood tests as part of the pilot programme.

In addition to features like its HealthTracks feature, which takes into account the user’s personal choices when calculating their lifetime risk for disease, 23andMe presently provides blood testing alternatives for its yearly members. According to the firm, the inclusion of blood biomarkers might enhance the precision of these forecasts and determine which treatments would have the most influence on an individual’s wellbeing.

Anne Wojcicki, CEO and cofounder of 23andMe explained: “We are truly impressed with Nightingale Health’s capabilities in blood biomarker testing.”

She continued: “Their work with public biobank projects and resulting publications have previewed the exciting potential for metabolomics in prediction. We believe this collaboration will ultimately help our customers lead longer, healthier lives.”

“This collaboration enables a globally unique feature set for 23andMe’s consumer health services,” Teemu Suna, CEO and founder of Nightingale Health, commented.